Imagine a replacement heart that doesn't just pump blood, but actually copies the shape and movement of a real human heart. It uses a special internal wall and valves to keep blood flowing naturally, which prevents the dangerous clots often seen in older machines. It's powered by a small external battery pack that the patient wears like a belt.
Current total artificial hearts often cause blood flow complications and rely on cumbersome external hardware. Many end-stage heart failure patients are ineligible for transplants, leaving them without a permanent solution.
A biomimetic TAH system consisting of two pumps, a drive line, and an intelligent control unit. It includes a proof-of-concept for wireless skin-penetrating energy transfer.
If you are a manufacturer dealing with high complication rates in artificial hearts — this project developed a system with a patented atrioventricular plane that reduces blood flow complications. It offers a lightweight 2kg design that improves patient quality of life.
If you are a clinic dealing with a shortage of donor hearts for end-stage patients — this project developed a permanent TAH solution. It allows surgeons to provide a long-term alternative for patients who do not qualify for transplant waiting lists.
If you are a tech firm dealing with cumbersome external power cables for implants — this project developed a proof-of-concept for wireless energy transfer via the skin. This reduces the number of external components from 3 down to 1.
Based on available project data, specific pricing and cost structures are not provided.
The project is currently in the stage of GLP animal trials and preparatory activities for first-in-man trials, meaning it is not yet at industrial scale.
The system features a unique patented construction of two atria and two ventricles separated by an atrioventricular plane.
The project aims to complete GLP animal trials and first-in-man (EFS) trials during the EIC project period.
The project period runs from 2022-04-01 to 2026-03-31, focusing on clinical trial preparation and initial human trials.
The project is led by a single Swedish SME, Scandinavian Real Heart AB, representing 100% of the industry ratio. This lean structure suggests a high level of control over IP but a heavy reliance on the coordinator's internal capabilities and a few external collaborations, such as the partnership with InvivoPower for wireless energy transfer.
Contact Scandinavian Real Heart AB in Sweden
Contact us to explore licensing opportunities for biomimetic heart technology.
